>>Description of the research protocol "Remarc LNH 2009-6B"

Double Blind Randomized Phase III Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP in First Line
Phase III study| Status : Ongoing (but closed to recruitment)

Additional details

Indication (or studied pathology) : Hémato-onco
Brugmann identifier : Remarc LNH 2009-6B
EudraCT identifier : 2008-008202-52
ClinicalTrials.gov identifier : NCT01122472


Involved department : Hemato-oncology
Principal investigator : Efira/Nifosi
Sponsor : Gelarc
Contact : Clinical Research Unit

>This protocol was approved by the UCL St Luc ethics committee.